21st International AIDS Conference (AIDS 2016)


Next Up -- Country-Specific HIV Vaccines

July 27, 2016

On behalf of IFARA, Fred Schaich spoke with Glenda Gray, MBBCH, F.C.Paed (SA), about HIV vaccine research presented at this year's International AIDS Conference. An upcoming vaccine study in South Africa is based on the RV144 Thai trial that showed the moderate efficacy of a combination of two preventive HIV vaccines. That compound was refined in order to target the specific variation of HIV common in South Africa, clade C. In addition, the vaccine's durability and potency were enhanced by combining a prevalent strain of the virus from a chronically HIV-infected South African and a viral envelope from an acutely infected person in the same country. Modeling studies for this upcoming placebo-controlled clinical trial estimate a 50% efficacy rate for the vaccine. One of the goals of this research is to better understand why some people acquire HIV despite being vaccinated. This means learning about how the virus genetically modifies itself in order to overcome the vaccine. Beyond studying whether the vaccine will provide a sufficient number of people with protection against the virus, there are real-world problems to overcome, Gray said. For one, the compound must be refrigerated, which can be problematic in Sub-Saharan Africa. The frequency of vaccine administration also presents a problem when trying to scale up its use.

Watch the video to learn more:

About the panelist:

  • Glenda Gray, MBBCH, F.C.Paed (SA), HIV Vaccine Trials Network

The video above has been posted on with permission from our partners at the International Foundation for Alternative Research in AIDS (IFARA). Visit IFARA's website or YouTube channel to watch more video interviews from the conference, as well as earlier meetings.

Barbara Jungwirth is a freelance writer and translator based in New York.

Follow Barbara on Twitter: @reliabletran.

Copyright © 2016 Remedy Health Media, LLC. All rights reserved.

Related Stories

NIH's Dr. Dieffenbach Shares Updates on HIV Vaccine Research From Second Day of AIDS 2016
Really Rapid Review -- AIDS 2016, Durban
This Week in HIV Research: Taking Treatment Four Days a Week Maintains Viral Suppression, and On-Demand PrEP Highly Effective

This article was provided by TheBodyPRO. It is a part of the publication The 21st International AIDS Conference (AIDS 2016).

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.